A Simple Switching Strategy for Inadequately Treated Patients with Schizophrenia to Olanzapine: Changes in Psychopathology and Subjective Well-being

M. Kluge; P. M. Wehmeier; R. W. Dittmann; F. Langer; J. Czekalla; M. Lehmann; F. H. Keßler; S. Beyenburg; D. Naber

doi:10.1055/s-2005-837764

Pharmacopsychiatry 2005; 38(1): 6-12
DOI: 10.1055/s-2005-837764

Original Paper

A Simple Switching Strategy for Inadequately Treated Patients with Schizophrenia to Olanzapine: Changes in Psychopathology and Subjective Well-being

M. Kluge¹ , P. M. Wehmeier¹ , R. W. Dittmann¹ ^, ² , F. Langer¹ , J. Czekalla¹ , M. Lehmann¹ , F. H. Keßler¹ , S. Beyenburg³ , D. Naber⁴

¹Lilly Deutschland GmbH, Medical Department, Bad Homburg, Germany
²University of Hamburg, Children’s Hospital, Psychosomatic Department, Hamburg, Germany
³Centre Hospitalier de Luxembourg, Department of Neurosciences, Luxembourg
⁴University of Hamburg, Psychiatric Department, Hamburg, Germany

The study was funded by Lilly Deutschland GmbH

Abstract

Introduction: The aim of the study was to assess the feasibility of abruptly switching inadequately treated psychotic outpatients from another oral antipsychotic to olanzapine and to evaluate subjective well-being under olanzapine. Methods: Previous medication was switched to olanzapine 10 mg/day and continued for 4 weeks (5-20 mg/day). Successful switch was predefined as no change or any improvement on the Clinical Global Impression-Improvement (CGI-I) scale after one week. A successful switch rate of ≥ 70 % was considered a positive study outcome. Well-being was evaluated using the Subjective Well-being under Neuroleptics (SWN) scale. Results: 198 patients (100 %) were switched to olanzapine. In 177 patients (89 %), CGI-I was unchanged (29 %) or improved (60 %) after one week of olanzapine treatment, indicating a positive study outcome (p < 0.001). SWN total score significantly improved from 127.9 (± 32.5) at baseline to 139.2 (± 31.5) at week 1, continuing to 149.3 (± 30.3) at week 4 (LOCF). Discussion: The findings suggest that an abrupt switch from another antipsychotic to olanzapine 10 mg/day can be performed successfully in psychotic patients, while rapidly improving subjective well-being.

Full Text

References

1 Amore M, Zazzeri N. Neuroleptic malignant syndrome after neuroleptic discontinuation. Prog Neuropsychopharmacol Biol Psychiatry. 1995; 19 1323-1334
2 Angermeyer M C, Matschinger H. Neuroleptics and quality of life. A patient survey. Psychiatr Prax. 2000; 27 64-68
3 Basson B R, Kinon B J, Taylor C C, Szymanski K A, Gilmore J A, Tollefson G D. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry. 2001; 62 231-238
4 Beasley CM J r, Hamilton S H, Crawford A M, Dellva M A, Tollefson G D, Tran P V, Blin O, Beuzen J N. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. 1997; 7 125-137
5 Brunner E, Domhof S, Langer F. Nonparametric analysis of longitudinal data in factorial experiments. Wiley Interscience 2002
6 Carriere P, Bonhomme D, Lemperiere T. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry. 2000; 15 321-329
7 Claxton A J, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001; 23 1296-1310
8 de Haan L, Weisfelt M, Dingemans P M, Linszen D H, Wouters L. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale. Psychopharmacology (Berl). 2002; 162 24-28
9 Franz M, Lis S, Pluddemann K, Gallhofer B. Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry. 1997; 170 422-425
10 Gaertner I, Altendorf K, Batra A, Gaertner H J. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses. J Clin Psychopharmacol. 2001; 21 215-222
11 Garcia-Cabeza I, Gomez J C, Sacristan J A, Edgell E, Gonzalez De Chavez M. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). BMC Psychiatry. 2001; 1 7
12 Hertling I, Philipp M, Dvorak A, Glaser T, Mast O, Beneke M ,. et al . Flupenthixol versus risperidone: subjective quality of life as an important factor for compliance in chronic schizophrenic patients. Neuropsychobiology.. 2003; 47 37-46
13 Ho B C, Nopoulos P, Flaum M, Arndt S, Andreasen N C. Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am J Psychiatry. 1998; 155 1196-1201
14 Ho B C, Miller D, Nopoulos P, Andreasen N C. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry. 1999; 60 658-663
15 Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology (Berl). 2002; 162 3-10
16 Kinon B J, Basson B R, Gilmore J A, Malcolm S, Stauffer V L. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry. 2000; 61 833-840
17 Lacro J P, Dunn L B, Dolder C R, Leckband S G, Jeste D V. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002; 63 892-909
18 Lambert M, Schimmelmann B G, Karow A, Naber D. Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical relevance. Pharmacopsychiatry. 2003; 36(Suppl 3) 181-190
19 Lee C T, Conde B J, Mazlan M, Visanuyothin T, Wang A, Wong M M,. et al . Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific. J Clin Psychiatry. 2002; 63 569-576
20 Löffler W, Kilian R, Toumi M, Angermeyer M C. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry. 2003; 36 105-112
21 Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol.. 1995; 10(Suppl 3) 133-138
22 Naber D, Moritz S, Lambert M, Pajonk F G, Holzbach R, Mass R ,. et al . Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001; 50 79-88
23 Osser D N, Sigadel R. Short-term inpatient pharmacotherapy of schizophrenia. Harv Rev Psychiatry. 2001; 9 89-104
24 Revicki D A, Genduso L A, Hamilton S H, Ganoczy D, Beasley CM J r. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res. 1999; 8 417-426
25 Ritchie C W, Chiu E, Harrigan S, Hall K, Hassett A, Macfarlane S ,. et al . The impact upon extrapyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int J Geriatr Psychiatry. 2003; 18 432-440
26 Ritsner M, Ponizovsky A, Endicott J, Nechamkin Y, Rauchverger B, Silver H ,. et al . The impact of side effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study. Eur Neuropsychopharmacol. 2002; 12 31-38
27 Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med. 1997; 337 809-815
28 Tempier R, Pawliuk N. Influence of novel and conventional antipsychotic medication on subjective quality of life. J Psychiatry Neurosci. 2001; 26 131-136
29 Tran P V, Hamilton S H, Kuntz A J, Potvin J H, Andersen S W, Beasley C J r, Tollefson G D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997; 17 407-418
30 Tranter R, Healy D. Neuroleptic discontinuation syndromes. J Psychopharmacol. 1998; 12 401-406
31 Tsuji S, Kikkawa S, Horiguchi J, Yamashita H, Kagaya A, Morinobu S, Yamawaki S. Meige syndrome with apraxia of lid opening after the discontinuation of sulpiride treatment. Pharmacopsychiatry. 2002; 35 155-156
32 Viguera A C, Baldessarini R J, Hegarty J D, van Kammen D P, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry. 1997; 54 49-55
33 Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res. 2000; 43 135-145
34 Wyatt R J. Research in schizophrenia and the discontinuation of antipsychotic medications. Schizophr Bull. 1997; 23 3-9

Dr. Michael Kluge

Max-Planck-Institute of Psychiatry

Kraepelinstr. 10

80804 Munich

Germany

Phone: ++49-89-30622-396

Fax: ++49-89-30622-548

Email: kluge@mpipsykl.mpg.de